Hal­da adds $126M to test oral drugs for prostate, breast can­cer

Con­necti­cut biotech Hal­da Ther­a­peu­tics, cre­at­ed by Arv­inas founder Craig Crews, has reeled in an­oth­er $126 mil­lion to start clin­i­cal test­ing of its oral mol­e­cules for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER